A high neutrophil-to-lymphocyte ratio as a potential marker of mortality in patients with Merkel cell carcinoma: A retrospective study

详细信息    查看全文

• 作者：Julia Zaragoza ; MD^a ; Thibault Kervarrec ; MSc^b ; Antoine Touzé ; PhD^c ; Martine Avenel-Audran ; MD^d ; Nathalie Beneton ; MD^e ; Eric Esteve ; MD^f ; Ewa Wierzbicka Hainaut ; MD^g ; Franç ; ois Aubin ; MD ; PhD^h ; Laurent Machet ; MD ; PhD^a ; Mahtab Samimi ; MD ; PhD^a ; ^c ; ^{mahtab.samimi@univ-tours.fr" class="auth_mail" title="E-mail the corresponding author}
• 关键词：absolute lymphocyte count ; absolute neutrophil count ; blood neutrophil-to-lymphocyte ratio ; Merkel cell carcinoma ; prognostic factor ; specific survival
• 刊名：Journal of the American Academy of Dermatology
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：75
• 期：4
• 页码：712-721.e1
• 全文大小：611 K

文摘

The prognostic relevance of a high blood neutrophil-to-lymphocyte ratio (NLR) has been reported in many cancers, although, to our knowledge, not investigated in patients with Merkel cell carcinoma (MCC) to date.

Objective

We assessed whether the NLR at baseline was associated with specific survival and recurrence-free survival in MCC.

Methods

We retrospectively included MCC cases between 1999 and 2015 and collected clinical data, blood cell count at baseline, and outcome. A Cox model was used to identify factors associated with recurrence and death from MCC.

Results

Among the 75 patients included in the study, a high NLR at baseline (NLR ≥4) was associated with death from MCC in univariate (hazard ratio 2.76, 95% confidence interval 1.15-6.62, P = .023) and multivariate (hazard ratio 3.30, 95% confidence interval 1.21-9.01, P = .020) analysis, but not with recurrence.

Limitations

Because of the retrospective design, we excluded patients with missing data and not all confounding factors that may influence the NLR were available.

Conclusion

A high NLR at baseline was independently associated with specific mortality in patients with MCC. The NLR seems to constitute an easily available and inexpensive prognostic biomarker at baseline.